NR

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress

Retrieved on: 
Monday, October 16, 2023
NR, IRC, Melanoma, Mucosal melanoma, ORR, Interleukin, TIL, Cancer, Oncology, ESMO, RECIST, Iovance Biotherapeutics, DOR, Patient, SAN, PFS, European Society for Medical Oncology, ICI, Pharmaceutical industry

The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial.

Key Points: 
  • The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial.
  • Patients with mucosal melanoma, which is rare and difficult to treat, have worse outcomes after anti–PD-1 therapy compared to patients with other melanoma subtypes.
  • The ORR assessed by an independent review committee (IRC) using RECIST v1.1 was 50% (95% CI: 21%–79%).
  • Treatment emergent adverse events (TEAEs) were consistent with known safety profiles of lymphodepleting chemotherapy and interleukin-2 (IL-2).

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Retrieved on: 
Monday, October 2, 2023
Research, General Health, Pharmaceutical, Consumer, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Seniors, Alternative Medicine, Vitamins, Supplements, Health, Exercise, DNA, Human, Nicotinamide adenine dinucleotide, Diabetes, Metabolism, NR, Nicotinamide riboside, Cardiovascular disease, ATP, Clinical trial, Ageing, NAD, ChromaDex, National Heart, Lung, and Blood Institute, Inflammation, Cell, Lung, Lupus, Bangladesh Technical Education Board, Trial of the century, Psoriasis, Amna Elhassan, NHLBI, Patient, Polyphosphate, Sleep deprivation, Conditional sentence, Smoking, Adenosine triphosphate, MRC Mitochondrial Biology Unit, NIH, Cell Reports, DNA repair, Pharmaceutical industry, Dietary supplement

The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.

Key Points: 
  • The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicotinamide riboside (NR) ingredient, Niagen, for the advancement of this research.
  • This is Dr. Sack’s fourth published study on NR, and the seventh clinical study overall, that demonstrates NR’s effectiveness in reducing inflammation, an important indicator of how the body is aging,” remarked Rob Fried, CEO of ChromaDex.
  • This is the third published human clinical study demonstrating that NR supplementation has a protective effect in healthy individuals and lays the foundation for future clinical research ( Elhassan et al.
  • Research suggests a depletion of NAD+ is associated with impaired inflammatory responses and innate immune dysfunction, indicating NAD+ levels may have a critical impact on the function of immune cells.

Keysight and Ettifos Successfully Conduct 3GPP Release 16 Sidelink Radio Conformance Test

Retrieved on: 
Thursday, September 28, 2023
Vehicle Technology, Automotive, Technology, Telecommunications, 5G, Hardware, 3GPP, NYSE, Element, NR, Mobile phone, Keysight

Keysight Technologies, Inc. (NYSE: KEYS) and Ettifos have successfully conducted a 3rd Generation Partnership Project (3GPP) Release 16 (Rel-16) Sidelink radio conformance test between the Ettifos SIRIUS 5G-V2X sidelink platform and Keysight's advanced test equipment, paving the way for 5G vehicle-to-everything (5G-V2X) advancements.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) and Ettifos have successfully conducted a 3rd Generation Partnership Project (3GPP) Release 16 (Rel-16) Sidelink radio conformance test between the Ettifos SIRIUS 5G-V2X sidelink platform and Keysight's advanced test equipment, paving the way for 5G vehicle-to-everything (5G-V2X) advancements.
  • Sidelink communications, a crucial feature for cellular vehicle-to-everything (C-V2X), allows vehicles to share information and other elements of the road system independent of the network.
  • With the completion of the conformance test, the Keysight and Ettifos equipment have been verified to be compliant with Rel-16 standards.
  • During the process, Keysight launched the first-to-market radio frequency (RF) physical layer test software apps supporting NR V2X for Keysight’s PathWave Signal Generation Desktop and X-Series RF vector signal generator.

Keysight EDA 2024 Integrated Software Tools Shift Left Design Cycles to Increase Engineering Productivity

Retrieved on: 
Tuesday, September 26, 2023
IOT (Internet of Things), Hardware, Electronic Design Automation, Technology, Software, Shift, Acceleration, Data management, ACPR, Doppler effect, Intellectual property, Communication, NR, ADS, NTN, EDA, API, Multidimensional Digital Pre-distortion, WLAN, Multimedia, QAM, VSA, Element, DVB, Advanced Design System, EVM, Risk, Algorithm, UE, Digital, 3GPP, MCS, NYSE, RF, DPD, FEM, Exploration, Printed circuit board, Medical imaging, Video game, Cable television, SATCOM

Keysight Technologies, Inc. (NYSE: KEYS) introduces Keysight EDA 2024, a tightly integrated suite of electronic design automation (EDA) software tools that ensures first pass success.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) introduces Keysight EDA 2024, a tightly integrated suite of electronic design automation (EDA) software tools that ensures first pass success.
  • This new integrated EDA software facilitates a “shift left” approach to increase productivity for engineers developing high speed, high frequency products in multiple applications.
  • Keysight EDA 2024 software includes new system and circuit design workflow integration, power amplifier modeling and simulation optimization, and Satcom design evolution enhancements.
  • Keysight EDA 2024 software suite offers the following shift left updates:
    The RF System Explorer integrates system architecture exploration and analysis features from SystemVue into Advanced Design System (ADS) to enable design sharing between system and circuit level workflows.

Radisys Announces Availability of Advanced FR1 4T4R 5G Solution Based on Qualcomm FSM200 5G RAN Platform

Retrieved on: 
Thursday, September 21, 2023
Software, Technology, Mobile, Wireless, Telecommunications, FR1, Product management, Connect, Qualcomm, FWA, FCAPS, NR, Original equipment manufacturer, Radisys, ARM, NETCONF, RAN, CU, CPE, Monolithic kernel, NSA, ACS, DU, Radio, CBRS, UES, 3GPP, SA, SVP, Mobile phone, Satellite navigation device

Radisys® Corporation , a global leader of open telecom solutions, today announced the availability of its award-winning 3GPP Release-17 compliant Connect RAN 5G FR1 software solution on the Qualcomm® FSM200 5G RAN Platform (FSM200xx), with advanced SA and NSA features including support for multiple bands (including CBRS bands) and high data throughput.

Key Points: 
  • Radisys® Corporation , a global leader of open telecom solutions, today announced the availability of its award-winning 3GPP Release-17 compliant Connect RAN 5G FR1 software solution on the Qualcomm® FSM200 5G RAN Platform (FSM200xx), with advanced SA and NSA features including support for multiple bands (including CBRS bands) and high data throughput.
  • Radisys’ Connect RAN FR1 solution bridges the gap in the availability of a multi-carrier 4T4R RAN solutions for outdoor small cell and compact macro industry segments.
  • Along with the Qualcomm FSM200xx baseband and advanced high-power radio capabilities, the Connect RAN 5G FR1 solution offers an efficient small cell design with low compute and memory requirements for high capacity and throughput.
  • Radisys’ collaboration with Qualcomm Technologies supports advanced Release-16 and Release-17 features like eURLLC, NR positioning and NR-U on the Qualcomm FSM200 5G RAN Platform.

Competition Remains Fierce in the Wireless IoT Connectivity Market as LPWA Networks Reach 5.3 Billion Connections in 2030

Retrieved on: 
Wednesday, September 20, 2023
SRW, IEEE 802.11ah, Bluetooth Low Energy, Wi-Fi, LPWAN, BLE, NR, Internet of things, Sierra Wireless, Research, History, LoRa, Bluetooth, Wi-Fi Alliance, Texas Instruments, Nordic Semiconductor, LPWA, Device, ZETA, Mobile phone

According to global intelligence firm ABI Research, Low-Power Wide Area Networks (LPWAN) will reach 5.3 billion connections in 2030.

Key Points: 
  • According to global intelligence firm ABI Research, Low-Power Wide Area Networks (LPWAN) will reach 5.3 billion connections in 2030.
  • But regardless of technology, LPWA solutions are increasingly confronted with complexity concerns as IoT users demand user-friendly, end-to-end IoT systems.
  • Though the wireless IoT networking market has a history of intense competition, trends in hybrid use cases suggest some IoT vendors are leaning toward collaboration.
  • These findings are from ABI Research's Connecting the IoT: Wide-Area and Short-Range Wireless Technologies Market Analysis application analysis report.

Competition Remains Fierce in the Wireless IoT Connectivity Market as LPWA Networks Reach 5.3 Billion Connections in 2030

Retrieved on: 
Wednesday, September 20, 2023
SRW, IEEE 802.11ah, Bluetooth Low Energy, Wi-Fi, LPWAN, BLE, NR, Internet of things, Sierra Wireless, Research, History, LoRa, Bluetooth, Wi-Fi Alliance, Texas Instruments, Nordic Semiconductor, LPWA, Device, ZETA, Mobile phone

According to global intelligence firm ABI Research, Low-Power Wide Area Networks (LPWAN) will reach 5.3 billion connections in 2030.

Key Points: 
  • According to global intelligence firm ABI Research, Low-Power Wide Area Networks (LPWAN) will reach 5.3 billion connections in 2030.
  • But regardless of technology, LPWA solutions are increasingly confronted with complexity concerns as IoT users demand user-friendly, end-to-end IoT systems.
  • Though the wireless IoT networking market has a history of intense competition, trends in hybrid use cases suggest some IoT vendors are leaning toward collaboration.
  • These findings are from ABI Research's Connecting the IoT: Wide-Area and Short-Range Wireless Technologies Market Analysis application analysis report.

Brixton Metals Yields up to 16.7% Copper, 52.5 g/t Gold and 4120 g/t Silver from Initial 2023 Surface Sampling Results at the Metla Target and the West Target, Thorn Project

Retrieved on: 
Wednesday, September 6, 2023
NR, Hyperaccumulators table – 3, Chicago Metallic Corporation, OTCQB, Talus, Thorn, BBB, Gold, Soil, Finnish Forest Research Institute, Camp Creek, Copper, CU, Mining, Phosphorus, Flour, Rare-earth element, Surveying, Trapping

While the majority of 2023 assay results are yet to be received, highlights from initial assay results are reported herein for the Metla, West, North, Bing, and Trapper targets.

Key Points: 
  • While the majority of 2023 assay results are yet to be received, highlights from initial assay results are reported herein for the Metla, West, North, Bing, and Trapper targets.
  • The West Target is located approximately 5km southwest of Thorn Camp and 6km west of Brixton’s Camp Creek Cu-Mo-Au porphyry target and hosts significant copper-silver mineralization.
  • Assay results from 2023 surface rock grab samples have returned 18 samples greater than 1.0% copper, including 11 samples greater than 5.0% copper.
  • The Metla Target claims were acquired by Brixton in 2020 and is an early-stage porphyry-epithermal target located 25km southeast of Thorn Camp.

Verizon, Ericsson and MediaTek advance the 5G low-cost, low-power device ecosystem

Retrieved on: 
Thursday, August 24, 2023
TDD, Hertz, RSS, NR, VZ, Internet of things, Human, Ericsson, Verizon Communications, Voice over NR, Redcap, Ecosystem, MediaTek, AR, SVP, Partnership, NYSE, LTE, Software, Mobile phone, Cable television

It also paves the way for enterprise IoT solutions like video surveillance, industrial sensors, and smart grids to run more efficiently on Verizon’s 5G network.

Key Points: 
  • It also paves the way for enterprise IoT solutions like video surveillance, industrial sensors, and smart grids to run more efficiently on Verizon’s 5G network.
  • Both voice and data sessions were completed using 5G technology over C-band TDD spectrum as well as 5G technology over 850 MHz FDD spectrum, in Verizon’s production network employing Verizon’s 5G standalone core.
  • Once this technology is deployed in the commercial network, Verizon will continue to work with consumer and business solution developers to accelerate 5G device development driving the entire ecosystem forward.
  • The introduction of New Radio (NR) RedCap devices will help expand the 5G ecosystem by caring for specific use cases with more efficient resource allocation.

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Prednisolone, Department of Urology, University of Virginia, HRR, NHA, NR, CI, Aes, OS, Cancer, MRK, Prognosis, RPF, AstraZeneca, Merck & Co., Prednisone, Death, HIV disease progression rates, Patient, Prostate cancer, Risk, Anemia, Propel, European, Nausea, BRCA, Metastasis, FDA, ITT, NYSE, Urology, Safety, Fatigue, Pharmaceutical industry, EU, Merck

As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).

Key Points: 
  • As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).
  • In the ITT population, common adverse events (AEs) in patients who received LYNPARZA plus abi/pred were anemia (45.5%), nausea (28.1%) and fatigue (27.9%).
  • Despite various treatment options available, the prognosis for mCRPC remains poor, with limited treatment options for patients whose cancer progresses following initial treatment.
  • This combination is also approved in the U.S. for the treatment of adult patients with deleterious or suspected deleterious BRCAm mCRPC.